Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04578873 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Oral QPX7831 SAD and MAD in Healthy Adults
A Phase 1 study, sponsored by Qpex Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT04578873 is a Phase 1 study that has completed, run by Qpex Biopharma. The registered enrollment target is 75 participants.
The verdict
NCT04578873, a Phase 1 study, has completed, sponsored by Qpex Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
This Phase 1 study will assess the safety, tolerability, and pharmacokinetics (PK) of QPX7831, a beta-lactamase inhibitor, when administered orally in single ascending doses and in multiple ascending doses to heathy adult subjects.
Interventions
- DRUG placebo comparator
- DRUG QPX7831
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2021-04-13 |
| Est. Completion | 2022-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04578873
The ClinicalTrials.gov registry entry for NCT04578873 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Qpex Biopharma, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo comparator is the first listed.
NCT04578873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04578873 about?
NCT04578873 is a clinical study titled "Phase 1 Oral QPX7831 SAD and MAD in Healthy Adults". This Phase 1 study will assess the safety, tolerability, and pharmacokinetics (PK) of QPX7831, a beta-lactamase inhibitor, when administered orally in single ascending doses and in multiple ascending doses to heathy adult subjects.
What is the current status of trial NCT04578873?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2021-04-13. Estimated completion is 2022-08-30.
What interventions are being tested in trial NCT04578873?
The interventions under investigation include: placebo comparator (DRUG), QPX7831 (DRUG).
Who is sponsoring clinical trial NCT04578873?
This trial is sponsored by Qpex Biopharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.